Allergan Smacked By Treasury Anti-Inversion Actions
This article was originally published in Scrip
Executive Summary
Allergan PLC investors panicked on April 4, driving shares of the firm down 22% in after-hours trading, over concerns new anti-inversion actions unleashed by the US Treasury Department would get in the way of the company's plans to merge under a $160bn deal with Pfizer Inc., whose own stock actually gained about 3%.